## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and conclusions as presented in the abstract; no access to methods, figures, tables, or supplementary data
- **Shared manuscript claim summary** The authors report a computational pipeline to identify natural compounds targeting the BRF2 protein, a TFIIIB complex component implicated in cancer. They modeled the BRF2 structure, performed virtual screening of a natural compound library via molecular docking, and conducted molecular dynamics simulations on the top four hits. They conclude that two compounds, Deacetyl lanatoside C and Neogitogenin, exhibit robust interaction characteristics with BRF2 and may serve as potential inhibitors to modulate selenoprotein synthesis and sensitize cancer cells to ferroptosis and apoptosis.
- **Visible evidence base** Abstract text only; no structural validation metrics, docking scores, simulation parameters, or interaction analyses are provided
- **Missing materials affecting confidence** Full methods, structural model coordinates, Ramachandran plot statistics, docking score distributions, MD simulation trajectories, hydrogen bonding analyses, free energy landscape plots, residue decomposition data, and any experimental validation

## Reviewer
- **Overall assessment** The abstract presents a plausible computational workflow for identifying putative BRF2 inhibitors, but the evidence provided is insufficient to evaluate the technical rigor or the validity of the conclusions. The central claims regarding robust interaction characteristics and therapeutic potential are not supported by the data visible in the abstract. The work may be of interest to computational drug discovery researchers, but the case for BRF2 as a druggable target and the specific compounds as viable leads is not established from the supplied material.
- **Who would be interested in the results, and why** Computational biologists and medicinal chemists working on RNA polymerase III-related pathways or natural product screening may find the approach relevant. Researchers studying selenoprotein synthesis or ferroptosis in cancer could also be interested, provided the computational findings are experimentally validated.
- **Major strengths** The abstract addresses a potentially important oncogenic target, BRF2, with a clear biological rationale linking it to cancer cell survival under oxidative stress. The workflow is logically structured, moving from structure modeling to docking to MD simulations, which is a standard and reasonable in silico approach.
- **Major Concerns** The abstract lacks quantitative results, such as docking scores, simulation stability metrics, or binding free energies, making it impossible to assess the robustness of the claimed interactions. The biological conclusions, including modulation of selenoprotein synthesis and sensitization to ferroptosis and apoptosis, are speculative and not supported by any experimental evidence in the abstract.
- **Minor Comments** The abstract would benefit from specifying the size and diversity of the natural compound library, the criteria for selecting the top four ligands, and the simulation timescale. The names of the compounds should be consistently formatted, and the phrase "robust interaction characteristics" should be defined with specific metrics.
- **Technical failings that need to be addressed before the case is established** No quantitative validation of the structural model is provided, such as Ramachandran plot percentages or refinement scores. Docking scores are mentioned but not reported. MD simulation outcomes, including root-mean-square deviation or fluctuation values, are absent. The link between computational binding and biological function is asserted without evidence.
- **Assessment against Nature-style criteria** Originality: moderate, as the target is relatively underexplored, but the approach is conventional. Scientific importance: potentially high if validated, but the abstract does not demonstrate it. Interdisciplinary readership: limited, as the work is purely computational and lacks experimental confirmation. Technical soundness: not assessable from the abstract due to missing data. Readability for nonspecialists: the abstract is understandable but uses jargon without sufficient context.
- **Recommendation posture** Currently not established from the provided evidence. The abstract suggests a promising starting point, but the claims require substantial additional data and likely experimental validation to be convincing.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The BRF2 protein structure was modeled, refined, and validated using the Ramachandran plot.
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract states that the structure was validated using a Ramachandran plot, but no specific validation metrics are given, such as the percentage of residues in favored or allowed regions. Without these numbers, the quality of the model cannot be assessed.
- **Why it matters** A poorly validated structural model would undermine all subsequent docking and simulation results, as the binding site and interactions would be unreliable.
- **Resolution test** Provide Ramachandran plot statistics, such as percent residues in favored, allowed, and outlier regions, along with any refinement scores like MolProbity or QMEAN.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The top four ligands exhibited low glide scores, and subsequent MD simulations showed robust interaction characteristics for Ligand 366 and Ligand 336.
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract does not report the actual glide scores, simulation timescales, or any MD-derived metrics such as root-mean-square deviation, root-mean-square fluctuation, or binding free energies. The term "robust interaction characteristics" is vague and unsupported.
- **Why it matters** Without quantitative data, the reader cannot judge whether the interactions are genuinely stable or merely artifacts of the simulation setup. The claim of robust binding is central to the paper's conclusion.
- **Resolution test** Report docking scores for all screened compounds and the top four, specify MD simulation length and ensemble, and provide quantitative measures of interaction stability, such as RMSD, RMSF, and MM-PBSA or similar binding free energy estimates.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Scientific importance
- **Claim pointer** These natural compounds may be potential inhibitors of BRF2, which could modulate the regulation of selenoprotein synthesis in cancer cells, and may offer a new therapeutic approach to sensitize cancer cells to ferroptosis and apoptosis.
- **Evidence pointer** Abstract, location not provided
- **Concern** The abstract extrapolates from computational binding to biological outcomes without any experimental data, such as cell-based assays, protein expression studies, or animal models. The link between BRF2 inhibition and ferroptosis or apoptosis is asserted but not demonstrated.
- **Why it matters** The therapeutic potential is a key selling point of the work, but without experimental validation, these claims remain speculative and could mislead readers about the practical applicability.
- **Resolution test** Include experimental validation, such as BRF2 activity assays, cell viability studies under oxidative stress, or measurement of selenoprotein levels, to support the proposed mechanism.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Compound naming
- **Evidence pointer** Abstract, location not provided
- **Issue** The compounds are referred to as "Ligand 366" and "Ligand 336" with common names in parentheses, but the formatting is inconsistent and the identifiers are not explained.
- **Required correction** Use consistent naming, such as "compound 366 (Deacetyl lanatoside C)" throughout, and clarify whether the numbers refer to library indices or internal identifiers.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Library description
- **Evidence pointer** Abstract, location not provided
- **Issue** The abstract mentions a "natural compound library" but does not specify its source, size, or diversity, which is essential for reproducibility.
- **Required correction** State the library name, number of compounds, and any filtering criteria used before docking.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Readability
- **Affected element** Biological context
- **Evidence pointer** Abstract, location not provided
- **Issue** The abstract introduces BRF2 and its role in cancer but does not explain why targeting it would specifically affect ferroptosis or apoptosis, leaving a logical gap for nonspecialist readers.
- **Required correction** Add one or two sentences connecting BRF2 function to these cell death pathways, citing relevant literature or prior findings.

## Risk / unsupported claims
- The claim that the BRF2 model is validated is unsupported due to missing Ramachandran plot statistics.
- The claim of "robust interaction characteristics" for Ligand 366 and Ligand 336 is unsupported without quantitative MD data.
- The claim that these compounds may modulate selenoprotein synthesis and sensitize cancer cells to ferroptosis and apoptosis is speculative and not assessable from the abstract.
- The overall therapeutic potential of BRF2 targeting is not established from the provided evidence.